Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 15.30 as of 2026-10-03T00:15:33.523Z.
Consensus retrieved: 2026-10-02T23:00:42.886Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-03T00:15:33.523Z.
Quote observation: 2026-10-02T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6f529dc2cb74a1dc48041e92b2e334a1e17b832483c02f9af0c0f071c3b429b6
Forward PE Ratio (15.30) = Dated Quote Price ($162.05) / Consensus Forward EPS ($10.59)
FORWARD PE RATIO
15.30
SECTOR MEDIAN · HEALTHCARE
18.71
median of 81 covered companies
CURRENT VS SECTOR MEDIAN
-18.23%
vs the sector median at left
ICON Public Limited Company
Market Cap
$12.41B
Forward PE Ratio
15.30
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ICON Public Limited Company (ICLR) | $12.41B | 15.30 |
| Penumbra, Inc. (PEN)vs › | $12.51B | 67.45 |
| Baxter International Inc. (BAX)vs › | $12.14B | 11.44 |
| Encompass Health Corporation (EHC)vs › | $11.88B | 19.60 |
| DaVita Inc. (DVA)vs › | $11.47B | 12.10 |
| Tempus AI, Inc. (TEM)vs › | $13.43B | N/A |
| Bio-Techne Corporation (TECH)vs › | $11.34B | 35.35 |
| The Cooper Companies, Inc. (COO)vs › | $11.10B | 12.53 |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.98B | 25.57 |
| Universal Health Services, Inc. (UHS)vs › | $10.64B | 7.78 |
Trailing P/E
38.0
reported TTM EPS
Forward P/E
15.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $10.59 implies +148.6% EPS growth vs the reported trailing $4.26.
At the dated quote price of $162.05, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $10.59 | $10.45 – $10.75 | 11 | 15.3x |
| 2027-12-31 | $11.88 | $10.88 – $12.31 | 11 | 13.6x |
| 2028-12-31 | $13.43 | $10.50 – $16.23 | 7 | 12.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
